血管生成素在糖尿病视网膜病变中的研究现状和进展  

The present research and progress of angiopoietin in diabetic retinopathy

作　　者：刘庆言 邵彦 李筱荣 Liu Qingyan;Shao Yan;Li Xiaorong(Tianjin Key Laboratory of Retinal Functions and Diseases,Tianjin Branch of National Clinical Research Center for Ocular Disease,Eye Institute and School of Optometry,Tianjin Medical University Eye Hospital,Tianjin 300383,China)

机构地区：[1]天津医科大学眼科医院、眼视光学院、眼科研究所,国家眼耳鼻喉疾病临床医学研究中心,天津市分中心,天津市视网膜功能与疾病重点实验室,天津300383

出　　处：《中华眼底病杂志》2022年第11期944-948,共5页Chinese Journal of Ocular Fundus Diseases

基　　金：国家自然科学基金(81900891);天津市临床重点学科建设项目(TJLCZDXKQ015);天津市临床重点学科建设项目(TJLCZDXKT004);天津市临床重点学科建设项目(TJLCZDXKM010)。

摘　　要：糖尿病视网膜病变(DR)是糖尿病最常见的微血管并发症之一,是糖尿病患者视力丧失的主要原因。血管生成素(Ang)是一类分泌蛋白的超家族,是调节血管内环境稳定、参与血管生成和修复、脂质代谢的血管生长因子,在DR发生发展中起重要作用,已经成为目前治疗DR的一个新靶点。随着对Ang研究的深入以及各种针对Ang药物的研发,未来有望为DR的治疗带来新的观点和策略。Diabetic retinopathy(DR)is one of the most common microvascular complications of diabetes,and it is the main cause of vision loss in diabetic patients.Angiopoietin(Ang),a superfamily of secreted proteins,is a vascular growth factor that regulates the stability of vascular environment,participates in angiogenesis and repair,and lipid metabolism.It plays an important role in the development of DR and has become a new target for the treatment of diabetic retinopathy.With the in-depth study of Ang and the research and development of various drugs for Ang,it is expected to bring new ideas and strategies for the treatment of DR in the future.

关 键 词：血管生成素类 糖尿病视网膜病变 受体蛋白质酪氨酸激酶类 脂质代谢 综述 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]